Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer

Prostate

Volumn 73, Issue 12, 2013, Pages 1291-1305

  Guerrero, Javier ^a   Alfaro, Iván E ^a   Gómez, Francisco ^a   Protter, Andrew A ^b   Bernales, Sebastián ^a,b  

^a Fundacion Ciencia para la Vida   (Chile)

^b Medivation Inc   (United States)

Author keywords

androgen receptor; MDV3100; microarray; nuclear translocation; prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER REGRESSION; CANCER SIZE; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL STRAIN HEK293; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN GENOME; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; XENOGRAFT;

ANDROGEN RECEPTOR; MDV3100; MICROARRAY; NUCLEAR TRANSLOCATION; PROSTATE CANCER;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HEK293 CELLS; HUMANS; MALE; MICE; MICE, SCID; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REMISSION INDUCTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84881034808     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22674     Document Type: Article

References (65)

1. Shelke AR, Mohile SG,. Treating prostate cancer in elderly men: How does aging affect the outcome ? Curr Treat Options Oncol 2011; 12 (3): 263-275.
2. Dutt SS, Gao AC,. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009; 5 (9): 1403-1413.
3. Lamont KR, Tindall DJ,. Androgen regulation of gene expression. Adv Cancer Res 2010; 107: 137-162.
4. Jenster G,. The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol 1999; 26 (4): 407-421.
5. Devlin HL, Mudryj M,. Progression of prostate cancer: Multiple pathways to androgen independence. Cancer Lett 2009; 274 (2): 177-186.
6. Yuan X, Balk SP,. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009; 27 (1): 36-41.
7. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL,. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10 (1): 33-39.
8. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Visakorpi T, Kallioniemi OP,. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57 (2): 314-319.
9. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T,. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001; 61 (9): 3550-3555.
10. Shiota M, Yokomizo A, Naito S,. Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011; 47: R25-R41.
11. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP,. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9 (4): 401-406.
12. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
13. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, Miyamoto M,. Novel mutations of androgen receptor: A possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63 (1): 149-153.
14. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooij HC, Trapman J, Mulder E,. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1990; 1052 (1): 187-194.
15. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H,. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81 (2): 242-251.
16. Hobisch A, Hoffmann J, Lambrinidis L, Eder IE, Bartsch G, Klocker H, Culig Z,. Antagonist/agonist balance of the nonsteroidal antiandrogen bicalutamide (Casodex) in a new prostate cancer model. Urol Int 2000; 65 (2): 73-79.
17. Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T, Aoki Y,. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010; 70 (7): 745-754.
18. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP,. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43 (4): 1809-1818.
19. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S,. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54 (11): 2861-2864.
20. Suzuki H, Akakura K, Komiya A, Aida S, Akimoto S, Shimazaki J,. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: Relation to antiandrogen withdrawal syndrome. Prostate 1996; 29 (3): 153-158.
21. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi A, McLeod DG, Srivastava S,. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006; 25 (28): 3905-3913.
22. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E,. Anti-androgens and the mutated androgen receptor of LNCaP cells: Differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31 (8): 2393-2399.
23. Dehm SM, Tindall DJ,. Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells. J Biol Chem 2006; 281 (38): 27882-27893.
24. Jung ME, Ouk S, Yoo D, Sawyers CL, Chen C, Tran C, Wongvipat J,. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010; 53 (7): 2779-2796.
25. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL,. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324 (5928): 787-790.
26. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
27. Schmittgen TD, Livak KJ,. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3 (6): 1101-1108.
28. Fung P, Peng K, Kobel P, Dotimas H, Kauffman L, Olson K, Eglen RM,. A homogeneous cell-based assay to measure nuclear translocation using beta-galactosidase enzyme fragment complementation. Assay Drug Dev Technol 2006; 4 (3): 263-272.
29. Gannon PO, Godin-Ethier J, Hassler M, Delvoye N, Aversa M, Poisson AO, Peant B, Alam Fahmy M, Saad F, Lapointe R, Mes-Masson AM,. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS ONE 2011; 5 (8): e12107.
30. Jiang C, Lee HJ, Li GX, Guo J, Malewicz B, Zhao Y, Lee EO, Lee JH, Kim MS, Kim SH, Lu J,. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: Identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 2006; 66 (1): 453-463.
31. Lu S, Wang A, Dong Z,. A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells. Mol Cancer Ther 2007; 6 (7): 2057-2064.
32. Makkonen H, Kauhanen M, Jaaskelainen T, Palvimo JJ,. Androgen receptor amplification is reflected in the transcriptional responses of vertebral-cancer of the prostate cells. Mol Cell Endocrinol 2011; 331 (1): 57-65.
33. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, Page ST, Coleman IM, Nguyen HM, Sun H, Nelson PS, Plymate SR,. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 2010; 120 (8): 2715-2730.
34. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, Diemer K, Muruganujan A, Narechania A, PANTHER: A library of protein families and subfamilies indexed by function. Genome Res 2003; 13 (9): 2129-2141.
35. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS,. Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther 2009; 8 (10): 907-916.
36. Calvo V, Beato M,. BRCA1 counteracts progesterone action by ubiquitination leading to progesterone receptor degradation and epigenetic silencing of target promoters. Cancer Res 2011; 71 (9): 3422-3431.
37. Thompson ME,. BRCA1 16 years later: Nuclear import and export processes. FEBS J 2010; 277 (15): 3072-3078.
38. Shanmugam I, Cheng G, Terranova PF, Thrasher JB, Thomas CP,., Li B,. Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ 2007; 14 (12): 2085-2094.
39. Royuela M, Ricote M, Parsons MS, Garcia-Tunon I, Paniagua R, de Miguel MP,. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate. J Pathol 2004; 202 (1): 41-49.
40. Godoy-Tundidor S, Cavarretta IT, Fuchs D, Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A, Culig Z,. Interleukin-6 and oncostatin M stimulation of proliferation of prostate cancer 22Rv1 cells through the signaling pathways of p38 mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Prostate 2005; 64 (2): 209-216.
41. Jaaskelainen T, Makkonen H, Palvimo JJ,. Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 11 2011; (4): 326-331.
42. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, Visakorpi T,. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69 (20): 8141-8149.
43. Yoshida T, Kinoshita H, Segawa T, Nakamura E, Inoue T, Shimizu Y, Kamoto T, Ogawa O,. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res 2005; 65 (21): 9611-9616.
44. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT,. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc Natl Acad Sci USA 2005; 102 (17): 6201-6206.
45. Claessens F, Denayer S, Van Tilborgh N, Kerkhofs S, Helsen C, Haelens A,. Diverse roles of androgen receptor (AR) domains in AR-mediated signaling. Nucl Recept Signal 2008; 6: e008.
46. He B, Minges JT, Lee LW, Wilson EM,. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 2002; 277 (12): 10226-10235.
47. Schaufele F, Carbonell X, Guerbadot M, Borngraeber S, Chapman MS, Ma AA, Miner JN, Diamond MI,. The structural basis of androgen receptor activation: Intramolecular and intermolecular amino-carboxy interactions. Proc Natl Acad Sci USA 2005; 102 (28): 9802-9807.
48. van Royen ME, Cunha SM, Brink MC, Mattern KA, Nigg AL, Dubbink HJ, Verschure PJ, Trapman J, Houtsmuller AB,. Compartmentalization of androgen receptor protein-protein interactions in living cells. J Cell Biol 2007; 177 (1): 63-72.
49. Kaku N, Matsuda K, Tsujimura A, Kawata M,. Characterization of nuclear import of the domain-specific androgen receptor in association with the importin alpha/beta and Ran-guanosine 5'-triphosphate systems. Endocrinology 2008; 149 (8): 3960-3969.
50. Zhou F, Zhao W, Zuo Z, Sheng Y, Zhou X, Hou Y, Cheng H, Zhou R,. Characterization of androgen receptor structure and nucleocytoplasmic shuttling of the rice field eel. J Biol Chem 2010; 285 (47): 37030-37040.
51. Saporita AJ, Zhang Q, Navai N, Dincer Z, Hahn J, Cai X, Wang Z,. Identification and characterization of a ligand-regulated nuclear export signal in androgen receptor. J Biol Chem 2003; 278 (43): 41998-42005.
52. Schutz SV, Cronauer MV, Rinnab L,. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem 2010; 109 (6): 1192-1200.
53. Cutress ML, Whitaker HC, Mills IG, Stewart M, Neal DE,. Structural basis for the nuclear import of the human androgen receptor. J Cell Sci 2008; 121 (Pt 7): 957-968.
54. Langley E, Zhou ZX, Wilson EM,. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 1995; 270 (50): 29983-29990.
55. Hodgson MC, Astapova I, Hollenberg AN, Balk SP,. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors. Cancer Res 2007; 67 (17): 8388-8395.
56. Masiello D, Cheng S, Bubley GJ, Lu ML, Balk SP,. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277 (29): 26321-26326.
57. Hodgson MC, Astapova I, Cheng S, Lee LJ, Verhoeven MC, Choi E, Balk SP, Hollenberg AN,. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists. J Biol Chem 2005; 280 (8): 6511-6519.
58. Ozers MS, Marks BD, Gowda K, Kupcho KR, Ervin KM, De Rosier T, Qadir N, Eliason HC, Riddle SM, Shekhani MS,. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 2007; 46 (3): 683-695.
59. Masiello D, Chen SY, Xu Y, Verhoeven MC, Choi E, Hollenberg AN, Balk SP,. Recruitment of beta-catenin by wild-type or mutant androgen receptors correlates with ligand-stimulated growth of prostate cancer cells. Mol Endocrinol 2004; 18 (10): 2388-2401.
60. Kolvenbag GJ, Furr BJ, Blackledge GR,. Receptor affinity and potency of non-steroidal antiandrogens: Translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1998; 1 (6): 307-314.
61. Zhou J, Liu B, Geng G, Wu JH,. Study of the impact of the T877A mutation on ligand-induced helix-12 positioning of the androgen receptor resulted in design and synthesis of novel antiandrogens. Proteins 2010; 78 (3): 623-637.
62. Brooke GN, Parker MG, Bevan CL,. Mechanisms of androgen receptor activation in advanced prostate cancer: Differential co-activator recruitment and gene expression. Oncogene 2008; 27 (21): 2941-2950.
63. Moehren U, Papaioannou M, Reeb CA, Grasselli A, Nanni S, Asim M, Roell D, Prade I, Farsetti A, Baniahmad A,. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: A novel role of AR mutation for prostate cancer development. FASEB J 2008; 22 (4): 1258-1267.
64. Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M,. Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ 2003; 10 (7): 761-771.
65. Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, Hautaniemi S, Janne OA,. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 2012; 73: 1570-1580.